Identification | Back Directory | [Name]
Mirtazapine-D3 | [CAS]
1216678-68-0 | [Synonyms]
Zispin-d3 Remeron-d3 Org-3770-d3 Mirtazapine-D3 1,2,3,4,10,14b-Hexahydro-2-(methyl-d3)-pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine 1,2,3,4,10,14b-Hexahydro-2-(methyl-d3)-pyrazino[2,1-α]pyrido[2,3-c][2]benzazepine | [Molecular Formula]
C17H19N3 | [MDL Number]
MFCD09841051 | [MOL File]
1216678-68-0.mol | [Molecular Weight]
265.353 |
Chemical Properties | Back Directory | [Appearance]
Off-White to Pale Yellow Solid | [Melting point ]
105-107°C | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White to Light Beige |
Hazard Information | Back Directory | [Chemical Properties]
Off-White to Pale Yellow Solid | [Uses]
An a 2-Adrenergic blocker. An analogue of Mianserin. Antidepressant | [Uses]
An α2-Adrenergic blocker; analogue of Mianserin. Antidepressant. | [in vivo]
Mirtazapine (intraperitoneal injection; 10-50 mg/Kg; 14 days) treatment normalizes heart rate, breath rate, anxiety levels and eliminates the hopping behavior observed in MeCP2-null mice, leading to improved phenotypic score[2]. Animal Model: | MeCP2 null mice[2] | Dosage: | 10-50 mg/Kg | Administration: | Intraperitoneal injection; 10-50 mg/Kg; 14 days | Result: | Restored the thickness of MeCP2-null mice somatosensory cortex, especially of layers II-III and VI. |
| [IC 50]
5-HT2 Receptor; 5-HT3 Receptor |
|
Company Name: |
Energy Chemical
|
Tel: |
021-58432009 400-005-6266 |
Website: |
http://www.energy-chemical.com |
Company Name: |
cjbscvictory
|
Tel: |
13348960310 13348960310 |
Website: |
https://www.weikeqi-biotech.com/ |
|